Highlighted- Recruiting Trials


Gilteritinib for ALK-positive Lung Cancer

Trial ID: NCT06225427
Phase: Phase 1
Status: Recruiting

Researchers are studying whether the targeted therapy gilteritinib may help treat ALK-positive lung cancer that has progressed after prior ALK inhibitors.


Gilteritinib in Advanced ALK-positive NSCLC

Trial ID: NCT07140016
Phase: Phase 1
Status: Recruiting

This study is evaluating the safety and recommended dose of gilteritinib in patients with advanced ALK-positive lung cancer who have previously received targeted therapies.


Hear directly from those who’ve participated in clinical trials:

Clinical trials play an important role in advancing new treatments for people living with ALK-positive lung cancer. In this video, hear directly from a patient who chose to participate in a clinical trial and shares what the experience was like—from deciding to enroll, to working with their care team, and why research continues to matter for the ALK+ community.

Watch the video below to learn more about their journey and perspective on participating in clinical research.